Longevity & AgingTET2 Blood Mutations Boost Immune Checkpoint Therapy in Solid Tumors
Clonal hematopoiesis — age-related mutations accumulating in blood stem cells — affects over 20% of solid tumor patients and was assumed to worsen outcomes. This study flips that narrative for TET2 mutations specifically. Using mouse bone marrow chimera models and data from over 60,000 human cancer patients, researchers found that TET2-mutant immune cells infiltrate tumors and enhance immune checkpoint therapy response. The mechanism: TET2-mutant macrophages become superior antigen-presenting cells, more effectively activating CD8+ killer T cells via IFNγ signaling. In both non-small cell lung cancer and colorectal adenocarcinoma cohorts, TET2-mutant clonal hematopoiesis correlated with improved ICT outcomes, suggesting this mutation could serve as a predictive biomarker for immunotherapy response.
